Proprietary AI analyst is now available

i-SENS Valuation Multiples

Discover i-SENS's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Sensortek, Seeing Machines, HUHUTECH, SAIMO and more.

i-SENS Overview

About i-SENS

i-SENS Inc is a Korean company which is engaged in the manufacture and sale of biosensors. The product portfolio of the company includes blood glucose monitoring systems, including blood glucose monitors, blood glucose meters, glucose monitors, blood glucose meter kits and blood sugar meters under the brand names of CareSens, MedTrust, BGStar, Barozen and others.


Founded

2000

HQ

South Korea

Employees

N/A

Website

i-sens.com

Financials (LTM)

Revenue: $214M
EBITDA: $17M

EV

$326M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

i-SENS Financials

i-SENS reported last 12-month revenue of $214M and EBITDA of $17M.

In the same LTM period, i-SENS generated $89M in gross profit, $17M in EBITDA, and had net loss of ($825K).

Revenue (LTM)


i-SENS P&L

In the most recent fiscal year, i-SENS reported revenue of $213M and EBITDA of $17M.

i-SENS is unprofitable as of last fiscal year, with gross margin of 38%, EBITDA margin of 8%, and net margin of (2%).

See analyst estimates for i-SENS
LTMLast FY202320242025202620272028
Revenue$214M$213M$172M$189M$205M
Gross Profit$89M$81M$69M$74M$81M
Gross Margin41%38%40%39%40%
EBITDA$17M$17M$15M$16M$9M
EBITDA Margin8%8%9%8%4%
EBIT Margin2%3%4%1%3%
Net Profit($825K)($3M)$2M($1M)($3M)
Net Margin(0%)(2%)1%(1%)(2%)
Net Debt-$82M---

Financial data powered by Morningstar, Inc.

i-SENS Stock Performance

i-SENS has current market cap of $279M, and enterprise value of $326M.

Market Cap Evolution


i-SENS's stock price is $9.75.

i-SENS share price decreased by 17.9% in the last 30 days.

i-SENS has an EPS (earnings per share) of $-0.12.

See more trading valuation data for i-SENS
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$326M$279M-6.5%-17.9%--$-0.12

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

i-SENS Valuation Multiples

i-SENS trades at 1.5x EV/Revenue multiple, and 19.7x EV/EBITDA.

See NTM and 2027E valuation multiples for i-SENS

EV / Revenue (LTM)


i-SENS Financial Valuation Multiples

As of June 24, 2026, i-SENS has market cap of $279M and EV of $326M.

i-SENS has a P/E ratio of (338.4x).

LTMLast FY202320242025202620272028
EV/Revenue1.5x1.5x1.9x1.7x1.6x
EV/EBITDA19.7x19.3x22.1x20.5x36.5x
EV/EBIT70.9x61.1x45.9x188.6x63.6x
EV/Gross Profit3.7x4.0x4.7x4.4x4.0x
P/En/m(83.4x)115.8x(239.5x)(83.4x)
EV/FCF(139.1x)(60.4x)(16.9x)67.9x(60.1x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified i-SENS Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

i-SENS Margins & Growth Rates

i-SENS grew revenue by 1% but EBITDA decreased by 4% in the last fiscal year.

In the most recent fiscal year, i-SENS reported gross margin of 38%, EBITDA margin of 8%, and net margin of (2%).

See estimated margins and future growth rates for i-SENS

i-SENS Margins

Last FY202420252026202720282029
Gross Margin38%39%40%43%
EBITDA Margin8%8%4%8%
EBIT Margin3%1%3%2%
Net Margin(2%)(1%)(2%)1%
FCF Margin(3%)3%(3%)0%

i-SENS Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth1%10%8%5%
Gross Profit Growth15%7%10%15%
EBITDA Growth(4%)8%(44%)81%
EBIT Growth(29%)(76%)197%(26%)
Net Profit Growth(160%)(148%)187%(160%)
FCF Growth(118%)(125%)(213%)(118%)

Data powered by FactSet, Inc. and Morningstar, Inc.

i-SENS Operational KPIs

i-SENS's Rule of 40 is 13% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

i-SENS's Rule of X is 20% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for i-SENS
LTMLast FY202320242025202620272028
Rule of 4014%13%---
Bessemer Rule of X23%20%---
S&M Expenses to Revenue-8%7%8%8%
G&A Expenses to Revenue-3%3%3%3%
R&D Expenses to Revenue10%10%10%10%10%
Opex to Revenue-36%36%38%37%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

i-SENS Competitors

i-SENS competitors include Sensortek, Seeing Machines, HUHUTECH, SAIMO, Gooch & Housego, Immersion, Smart Eye, Gefran, General Oceans and Aeluma.

Most i-SENS public comparables operate across Sensors & Monitoring and Industry 4.0.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Sensortek1.3x-13.7x-
Seeing Machines5.7x3.7x(70.9x)50.0x
HUHUTECH11.9x-(15.4x)-
SAIMO5.2x-9.4x-
Gooch & Housego2.0x1.8x13.1x11.5x
Immersion0.2x-2.1x-
Smart Eye8.3x6.4x668.9x27.9x
Gefran0.8x0.8x5.2x5.2x

This data is available for Pro users. Sign up to see all i-SENS competitors and their valuation data.

Start Free Trial

i-SENS VC Funding History

Before going public, i-SENS raised $10M in total equity funding, across 1 round.


i-SENS Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Nov-21Series ADSC Investment; Korea Investment Partners; Mirae Asset Venture Investment$10M--

Acquisitions by i-SENS

i-SENS has acquired 2 companies to date.

Last acquisition by i-SENS was on May 17th 2023. i-SENS acquired AgaMatrix for $27M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by i-SENS

AgaMatrix
CoaguSense
Description
AgaMatrix is a Salem, New Hampshire-headquartered developer of diabetes management devices. Its WaveSense technology powers blood glucose meters that correct for hematocrit, temperature, and strip variations, achieving high accuracy. The product line includes JAZZ and PRECIO meters, with Zero-Click data management software. Protected by over 160 patents, the FDA-cleared devices are distributed globally through partnerships with retailers and pharma companies.
CoaguSense is a manufacturer of point-of-care PT/INR monitoring systems for anticoagulation management. U.S.-based, its devices deliver lab-accurate results in seconds using fingerstick samples. Distributed to clinics and home users, the systems support warfarin therapy with data connectivity to EHRs.
HQ CountryUnited StatesUnited States
HQ City
-
San Francisco, CA
Deal Date17 May 20231 Dec 2016
Valuation$27Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all i-SENS acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by i-SENS

i-SENS has invested in 1 company to date.

Latest investment by i-SENS was on November 6th 2023. i-SENS invested in Caremedi in their $20M Series B round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by i-SENS

Caremedi
Description
-
HQ CountrySouth Korea
HQ City
-
Deal Date6 Nov 2023
RoundSeries B
Raised$20M
InvestorsAJU IB Investment Co; i-SENS; Korea Investment Partners; Company K Partners; Atinum Investment
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all i-SENS investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About i-SENS

Who are competitors of i-SENS?i-SENS main competitors include Sensortek, Seeing Machines, HUHUTECH, SAIMO, Gooch & Housego, Immersion, Smart Eye, Gefran, General Oceans, Aeluma.

See public comps similar to i-SENS

Lists including i-SENS

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial